1. The clinical investigator is vulnerable to medicolegal suit for experimenting with improved drugs. The clinical investigator is now frightened by the threat of malpractice litigation. There is question whether current insurance policies will protect the clinical investigator, because this coverage is designed for the standard practice of medicine, not for research.
Dramatic news stories of irresponsible research
studies have alarmed the public and caused it to lose confidence.
3. The clinical investigator complains that modern regulations appear to be too cumbersome and often impractical.
4. Recent publications condemn the practice of controlled blind studies and experimentation on human beings.
5. The convict, the derelict, and the patient in the mental institution have the same rights as the patient in private practice.
6. If the nation is to benefit from new agents, it must allow for the calculated risks inherent in testing. The benefits resulting from a drug must be weighed against the damage it may do. 7. Federal agencies have been appropriating large sums of money for biomedical research ($1.2 million in 1965) and now require that certain criteria be met for the protection of patients used for study.
8. There is a great shortage of well trained investigators in clinical pharmacology. 9. Public indignation resulting from a few unfortunate episodes has caused what seem to be overly stringent regulations possibly jeopardizing the search for better drugs.
The physician's legal responsibility in the clinical testing of drugs was discussed at length. Two sentences read: "The clinical investigator must assume personal responsibility for dispensing, administration, storage and records of test drugs. He may delegate this supervision to an associate."
One wonders why the help of other professional groups, such as pharmacy and nursing, is not more openly sought and acknowledged in the handling of investigational drugs. Few clinical investigators can, for example, match the system devised by pharmacists Robert W. Case at the Roswell-Park Memorial Institute at Buffalo (see page 282) or Milton Skolaut at The Clinical
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Center of the National Institutes of Health, and others, for controlling the distribution of investigational drugs and maintaining a record of them. Few clinical investigators have more than a cursory knowledge of formulation techniques and procedures or proper labeling and storage re 1 quirements. Acknowledgement that clinical · testing of drugs is a team effort -yes, with the physician as team captain -would be most helpful. Questions of professional liability insurance and indemnification occupied an important part of the discussion at the conference. It was recommended for the protection of both the investigator and the patient that pharmaceutical companies provide either the cost of liability insurance or indemnification for the investigator for any damages he has to pay as a result of claims or litigation based upon injuries occurring to the patient allegedly as the result of clinical investigation.
Another panel called the term clinical pharmacology vague and stated that it should not be used without qualification. No alternative term was proposed. This panel also encouraged development of a truly professional group of science reporters and suggested that the services of a good science writer may be a justifiable part of investigational costs. The need for a large investment in the methodology of record handling was recognized.
The panel concerned with the rights and protection of patients emphasized the importance of prior review and approval of a study project by an independent, qualified group. Such review boards should consult with the investigator to improve all aspects of the study.
The difference in patient-physician relationship in medical practice and research was explored. In practice, the patient seeks the physician; in research, specific patients are sought and selected. In practice, diagnosis, treatment, and care are provided for the specific condition as long as needed; in research, treatment lasts only during the period of investigation. In practice, the patient pays the physician, whereas study patients are often paid or given care in exchange.
The Fourth Bethesda conference sponsored by the American College of Cardiology represents an important contribution to understanding of some of the perplexing problems in the evaluation of drugs. Needless to say, not all problems were solved, but progress was made.
